In a significant milestone, HoloCare, a surgical health tech startup, has received UKCA and CE mark certification, paving the way for its launch into five hospitals in the UK and EU. The innovative surgical hologram technology is set to be deployed at Leeds Teaching Hospitals NHS Trust in the UK, with the aim of enhancing surgical precision and efficiency.
By creating interactive 3D holograms of individual patient’s organs, the software allows surgeons to meticulously plan and personalize surgeries according to the patient’s unique anatomy. This improved spatial awareness is expected to lead to more efficient and accurate operations, ultimately benefiting patient surgery outcomes and clinician wellbeing, as well as reducing waiting times.
The platform will initially focus on improving the quality of planning for complex liver resections, commonly used in the treatment of liver and bowel cancer. Professor Peter Lodge, a consultant surgeon at Leeds Teaching Hospitals, expressed optimism about the potential of this technology to significantly improve decision-making for liver surgery and other liver cancer therapies.
HoloCare is also set to launch in additional European hospitals in 2024, with plans for expansion beyond Europe. The company’s CE mark approval, based on clinical research carried out in collaboration with Oslo University Hospital, is a testament to the confidence in its solution.
The team at Leeds Teaching Hospitals will undergo training with the new technology, and their feedback on its impact on patient care will be closely evaluated. This development aligns with HoloCare’s vision to revolutionize surgical practices and improve patient outcomes through its cutting-edge technology.
